Medipattern narrows losses in Q1

Medipattern has posted a net loss of  CAD $717,288 (U.S. $678,895) for the first quarter of fiscal 2010, which ended Sept. 30. Despite the loss, it represented a 35 percent improvement over the CAD1.1 million ($1 million U.S.) loss reported during the same period last year.

Revenue for the Toronto, Ontario-based company was CAD2.12 million ($2.01 million U.S.) in the first quarter compared to approximately CAD76,000 ($72,000 U.S.) posted in the first quarter last year.

Medipattern's CEO Jeff Collins said the drop in earnings was due to timing issues connected with a shift from a traditional licensing model to an annuity model. "As an inducement under the long-term contract, we give customers a grace period before payments begin, which impacted our results in the quarter," Collins said.

Total expenses for the first quarter of the 2010 fiscal year declined 39 percent to CAD720,000 ($680,000 U.S.) from CAD1.18 million ($1.12 million U.S.) in the same period last year, mostly as a result of reduced sales and marketing costs, research & development and administrative costs.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.